Clinical Trial Update: Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

View source ↗

Summary

This completed clinical trial analyzes healthcare costs among patients with Chronic Myeloid Leukemia treated with dasatinib or nilotinib in commercial and Medic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myeloid Leukemia (CML) | Status: COMPLETED